Literature DB >> 12602504

Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy.

E Anthony Jones1.   

Abstract

There appears to be a consensus that hepatic encephalopathy (HE) is a metabolic encephalopathy with a multifactorial pathogenesis. One of the factors considered to be important in the pathogenesis of HE is ammonia. However, the mechanisms by which ammonia contributes to the manifestations of HE remain poorly defined. Ammonia could be more definitively implicated in the pathogenesis of HE if its effects can be shown to lead to an enhancement of inhibitory neurotransmission. In this context the effects of ammonia on the GABA (gamma-aminobutyric acid) neurotransmitter system may be relevant. Ammonia, at the modestly increased concentrations that commonly occur in precoma HE (0.15 mM-0.75 mM), has been shown to increase GABA-induced chloride current in cultured neurons, probably by modifying the affinity of the GABA(A) receptor for GABA. Comparable ammonia concentrations also enhanced synergistically the binding of a GABA agonist and a benzodiazepine (BZ) agonist to the GABA(A) receptor complex, phenomena which would enhance the neuroinhibitory effects of these ligands. Also, GABA increased the potency of ammonia-induced enhancement of the binding of a BZ agonist to the GABA(A) receptor complex, and brain levels of BZ agonists are elevated in liver failure. In addition, ammonia has been shown to inhibit astrocytic uptake of GABA by 30%-50%, an effect which would increase the synaptic availability of GABA at GABA(A) receptors. Furthermore, increased ammonia concentrations upregulate the peripheral-type benzodiazepine receptor in the outer membrane of astroglial mitochondria, thereby enhancing astrocytic mitochondrial synthesis and release of neurosteroids. Some neurosteroids, for example tetrahydroprogesterone (THP) and tetrahydrodeoxycorticosterone (THDOC), are potent agonists of the GABA(A) receptor complex, on which there are specific binding sites for neurosteroids, that are distinct from those for BZs and barbiturates. Tetrahydroprogesterone and tetrahydrodeoxycorticosterone levels were found to be increased in a mouse model of acute liver failure, and, when THP or THDOC was injected into normal mice, sedation and Alzheimer type II astrocytic changes in the cortex, striatum, and hypothalmus were induced. Each of these direct or indirect effects of ammonia on the GABA neurotransmitter system has the potential of increasing inhibitory neurotransmission, and, hence, contributing to the manifestations of HE.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12602504     DOI: 10.1023/a:1021949616422

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  31 in total

1.  Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure.

Authors:  A S Basile; R D Hughes; P M Harrison; Y Murata; L Pannell; E A Jones; R Williams; P Skolnick
Journal:  N Engl J Med       Date:  1991-08-15       Impact factor: 91.245

Review 2.  Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy.

Authors:  A S Basile; E A Jones
Journal:  Hepatology       Date:  1997-06       Impact factor: 17.425

3.  Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor.

Authors:  M D Majewska; N L Harrison; R D Schwartz; J L Barker; S M Paul
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

Review 4.  Neurosteroids and GABAA receptor function.

Authors:  J J Lambert; D Belelli; C Hill-Venning; J A Peters
Journal:  Trends Pharmacol Sci       Date:  1995-09       Impact factor: 14.819

5.  Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy.

Authors:  M Olasmaa; J D Rothstein; A Guidotti; R J Weber; S M Paul; S Spector; M L Zeneroli; M Baraldi; E Costa
Journal:  J Neurochem       Date:  1990-12       Impact factor: 5.372

6.  The contribution of endogenous benzodiazepine receptor ligands to the pathogenesis of hepatic encephalopathy.

Authors:  A S Basile
Journal:  Synapse       Date:  1991-02       Impact factor: 2.562

7.  Acute liver failure and hyperammonemia increase peripheral-type benzodiazepine receptor binding and pregnenolone synthesis in mouse brain.

Authors:  Y Itzhak; A Roig-Cantisano; R S Dombro; M D Norenberg
Journal:  Brain Res       Date:  1995-12-24       Impact factor: 3.252

8.  Ammonia potentiates GABAA response in dissociated rat cortical neurons.

Authors:  K Takahashi; H Kameda; M Kataoka; K Sanjou; N Harata; N Akaike
Journal:  Neurosci Lett       Date:  1993-03-05       Impact factor: 3.046

9.  Dual action of pentobarbitone on GABA binding: role of binding site integrity.

Authors:  M Willow; G A Johnston
Journal:  J Neurochem       Date:  1981-11       Impact factor: 5.372

10.  Astrocytes and neurosteroids: metabolism of pregnenolone and dehydroepiandrosterone. Regulation by cell density.

Authors:  Y Akwa; N Sananès; M Gouézou; P Robel; E E Baulieu; C Le Goascogne
Journal:  J Cell Biol       Date:  1993-04       Impact factor: 10.539

View more
  16 in total

Review 1.  Pathogenesis of Hepatic Encephalopathy in Chronic Liver Disease.

Authors:  Rafael Ochoa-Sanchez; Christopher F Rose
Journal:  J Clin Exp Hepatol       Date:  2018-08-18

2.  Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; Puneeta Tandon; Florence Wong; Patrick S Kamath; Scott W Biggins; Guadalupe Garcia-Tsao; Jennifer Lai; Michael B Fallon; Paul J Thuluvath; Hugo E Vargas; Benedict Maliakkal; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy
Journal:  Aliment Pharmacol Ther       Date:  2019-04-29       Impact factor: 8.171

3.  Expression of gamma-aminobutyric acid A receptor subunits alpha1, beta1, gamma2 mRNA in rats with hepatic encephalopathy.

Authors:  Xiao-Qing Li; Lei Dong; Zhong-Hua Liu; Jin-Yan Luo
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

Review 4.  Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?

Authors:  Lise Lotte Gluud; Gitte Dam; Mette Borre; Iñigo Les; Juan Cordoba; Giulio Marchesini; Niels Kristian Aagaard; Hendrik Vilstrup
Journal:  Metab Brain Dis       Date:  2012-12-29       Impact factor: 3.584

5.  Efficient bioconversion of L-glutamate to γ-aminobutyric acid by Lactobacillus brevis resting cells.

Authors:  Xiufeng Shi; Chuanyou Chang; Shenxi Ma; Yibing Cheng; Jun Zhang; Qiang Gao
Journal:  J Ind Microbiol Biotechnol       Date:  2016-05-07       Impact factor: 3.346

6.  Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial.

Authors:  Jasmohan S Bajaj; Zain Kassam; Andrew Fagan; Edith A Gavis; Eric Liu; I Jane Cox; Raffi Kheradman; Douglas Heuman; Jessica Wang; Thomas Gurry; Roger Williams; Masoumeh Sikaroodi; Michael Fuchs; Eric Alm; Binu John; Leroy R Thacker; Antonio Riva; Mark Smith; Simon D Taylor-Robinson; Patrick M Gillevet
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

Review 7.  Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint.

Authors:  Samir Ahboucha; Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 8.  Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.

Authors:  Halina Cichoż-Lach; Agata Michalak
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 9.  Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions.

Authors:  Duminda Suraweera; Vinay Sundaram; Sammy Saab
Journal:  Gut Liver       Date:  2016-07-15       Impact factor: 4.519

10.  Benzodiazepines and risk for hepatic encephalopathy in patients with cirrhosis and ascites.

Authors:  Lisbet Grønbæk; Hugh Watson; Hendrik Vilstrup; Peter Jepsen
Journal:  United European Gastroenterol J       Date:  2017-08-23       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.